These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 25679803)

  • 1. Optimal cutoff value of P2Y12 reaction units to prevent major adverse cardiovascular events in the acute periprocedural period: post-hoc analysis of the randomized PRASFIT-ACS study.
    Nakamura M; Isshiki T; Kimura T; Ogawa H; Yokoi H; Nanto S; Takayama M; Kitagawa K; Ikeda Y; Saito S
    Int J Cardiol; 2015 Mar; 182():541-8. PubMed ID: 25679803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
    Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
    J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
    Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
    J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
    Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB;
    Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching acute coronary syndrome patients from prasugrel to clopidogrel.
    Kerneis M; Silvain J; Abtan J; Cayla G; O'Connor SA; Barthélémy O; Vignalou JB; Beygui F; Brugier D; Martin R; Collet JP; Montalescot G
    JACC Cardiovasc Interv; 2013 Feb; 6(2):158-65. PubMed ID: 23428007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in Japanese patients with stable coronary artery disease.
    Nishi T; Ariyoshi N; Nakayama T; Fujimoto Y; Sugimoto K; Takahara M; Wakabayashi S; Koshizaka M; Hanaoka H; Kobayashi Y
    Circ J; 2015; 79(11):2439-44. PubMed ID: 26310876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial.
    Nicolau JC; Bhatt DL; Roe MT; Lokhnygina Y; Neely B; Corbalán R; Leiva-Pons JL; Martinez F; Goodman SG; Winters KJ; Verheugt FW; Armstrong PW; White HD; Fox KA; Prabhakaran D; Ohman EM;
    Am Heart J; 2015 Oct; 170(4):683-694.e3. PubMed ID: 26386792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
    Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C
    Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in P2Y12 reaction units after switching treatments from prasugrel to clopidogrel in Japanese patients with acute coronary syndrome followed by elective coronary stenting.
    Ueno T; Koiwaya H; Sasaki KI; Katsuki Y; Katsuda Y; Murasato Y; Shimamatsu J; Umeji K; Otsuka Y; Kawasaki T; Shibata Y; Fukumoto Y
    Cardiovasc Interv Ther; 2017 Oct; 32(4):341-350. PubMed ID: 27488859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial.
    Diodati JG; Saucedo JF; French JK; Fung AY; Cardillo TE; Henneges C; Effron MB; Fisher HN; Angiolillo DJ
    Circ Cardiovasc Interv; 2013 Oct; 6(5):567-74. PubMed ID: 24065443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of initial clinical presentation on clopidogrel low response.
    Landel JB; Bauters A; Delhaye C; Bonello L; Sudre A; Susen S; Bauters C; Lablanche JM; Lemesle G
    Arch Cardiovasc Dis; 2013 Nov; 106(11):593-600. PubMed ID: 24070598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VERifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel.
    Cubero Gómez JM; Acosta Martínez J; Mendias Benítez C; Díaz De La Llera LS; Fernández-Quero M; Guisado Rasco A; Villa Gil-Ortega M; Sánchez González Á
    Acta Cardiol; 2015 Dec; 70(6):728-34. PubMed ID: 26717223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
    Leoncini M; Toso A; Maioli M; Angiolillo DJ; Giusti B; Marcucci R; Abbate R; Bellandi F
    JACC Cardiovasc Interv; 2013 Feb; 6(2):169-79. PubMed ID: 23428009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
    Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
    Gurbel PA; Erlinge D; Ohman EM; Neely B; Neely M; Goodman SG; Huber K; Chan MY; Cornel JH; Brown E; Zhou C; Jakubowski JA; White HD; Fox KA; Prabhakaran D; Armstrong PW; Tantry US; Roe MT;
    JAMA; 2012 Nov; 308(17):1785-94. PubMed ID: 23117779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
    Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G
    Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
    Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G
    Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.
    Diodati JG; Saucedo JF; Cardillo TE; Jakubowski JA; Henneges C; Effron MB; Lipkin FR; Walker JR; Duvvuru S; Sundseth SS; Fisher HN; Angiolillo DJ
    Thromb Haemost; 2014 Aug; 112(2):311-22. PubMed ID: 24718367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
    Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
    J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L
    Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.